Diabetes drug liraglutide linked to lower risk of cardiovascular events
(Karolinska Institutet) Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death. The study, led by researchers from Karolinska Institutet in Sweden, is published in The Lancet Diabetes& Endocrinology.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | International Medicine & Public Health | Stroke | Study | Sweden Health | Victoza